STK11 and non-small cell lung carcinoma: This may also be the case in KRASm NSCLC if KEAP1 or LKB1/STK11 co-mutations are present, as these seem to have a detrimental effect on KRASm NSCLC patient outcomes, particularly when a single-agent ICI is used.